- Chimeric Therapeutics (ASX:CHM) announces positive in vitro data for CHM 1301, its next-generation chlorotoxin CAR NK cell therapy program
- CHM 1301 merges Chimeric’s CLTX CAR T cell therapy with the efficacy of its NK cell platform to develop an advanced CLTX CAR NK cell therapy
- The drug increases cell killing in ovarian cancer by 260 per cent and increases pancreatic cancer cell killing by 300 per cent
- Chimeric is advancing the CHM 1301 program to its next stage of preclinical development and believes it can be used beyond glioblastoma treatment
- CHM shares are up 24.1 per cent, trading at 3.6 cents at 12:53 pm AEDT
Chimeric Therapeutics (ASX:CHM) has announced positive in vitro data for CHM 1301, the company’s next-generation chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell therapy program.
CHM 1301 has been created by merging the newly disclosed effectiveness of CHM 1101, Chimeric’s CLTX CAR T cell therapy, with the efficacy and readily available nature of CHM 02012, Chimeric’s NK cell platform, to develop an advanced CLTX CAR NK cell therapy.
CHM 1301 was studied in pre-clinical in vitro models of human ovarian cancer and pancreatic cancer, where it demonstrated significant efficacy in killing cancer cells.
The drug increased cell killing in ovarian cancer by around 260 per cent, compared to first-generation CHM 0201 cells, and in pancreatic cancer, cell killing increased by 300 per cent.
“We believe this work is highly impactful as it demonstrates the synergy of the assets that currently exist in Chimeric’s portfolio, the ability for Chimeric to expand into new disease areas and the potential for enhanced efficacy with an off-the-shelf version of our CHM 1101 CAR,” CHM CEO and Managing Director Jennifer Chow said.
“Being able to achieve this success through our cost-effective, academic collaboration with Dr David Wald at Case Western Reserve University also enables Chimeric to continue to build out a promising next-generation pipeline while focusing resources on our current clinical stage asset.”
Based on this success, Chimeric is advancing the CHM 1301 program to its next stage of preclinical development, with the help of its recently developed armoured NK cell platform (CHM 0301).
The company is aiming to further enhance cell potency and resistance against the immunosuppressive solid tumour micro-environment and claims this milestone will address additional unmental solid tumour needs beyond glioblastoma.
CHM shares were up 24.1 per cent, trading at 3.6 cents at 12:53 pm AEDT.